A study of 10,076 adults aged 80 or older with chronic kidney disease (CKD), released on 24 October 2026 at ASN Kidney Week 2026 in Denver, linked starting an SGLT2 inhibitor to 18% lower all-cause mortality over two years.
Major adverse kidney events fell by 22%, but the drugs were associated with higher risks of heart attack, acute heart failure and acute kidney injury; overall major cardiovascular events did not change significantly.
The study used real-world electronic health records, not a randomised trial; its authors say patients this old need an individual risk-benefit assessment and close monitoring.
SGLT2 inhibitors - dapagliflozin, empagliflozin, canagliflozin, ertugliflozin - lower blood sugar by making the kidneys pass glucose in urine.
SGLT2 is a protein in the kidney's proximal tubule that pulls filtered glucose back into the blood. Blocking it lets that glucose leave in urine, lowering blood sugar in Type 2 diabetes. The drugs also slow CKD progression, reduce dialysis risk and cut heart-failure flare-ups.
Simple Analogy: Like opening a drain so excess sugar flows out instead of being recycled.
Professional body of kidney specialists; organises Kidney Week, where the study was presented; founded 1966
India's apex biomedical research body; ran the ICMR-INDIAB national diabetes survey published in The Lancet Diabetes & Endocrinology in 2023
GS Paper III > Science and Technology > Health and biotechnology; Prelims > Drugs and diseases in news
Gradual, long-term loss of kidney function; diabetes and high blood pressure are its leading causes
Research drawn from routine records such as electronic health records rather than a controlled trial; shows association, not proof of cause